Cellnovo mobile diabetes management system wins EU approval
23 November 2011
Cellnovo has received CE Mark approval for its diabetes management system built around
mobile, wireless technology.
The system includes an
insulin patch pump, a wireless, touchscreen handset with a built-in
blood glucose monitor, and an extendable applications set.
The Cellnovo handset wirelessly
receives and transmits real-time data to a portal for patients and
caregivers to use. This means that patients no longer have the
burden of keeping meticulous journals, and that the data collected
is incredibly accurate and consistent, ensuring optimal monitoring
and treatment of the disease.
"This is Cellnovo's
first step in a journey to bring this mobile diabetes management system
to the world," says William McKeon, Chief Executive Officer of Cellnovo.
The Cellnovo diabetes management system
"Cellnovo has created the first insulin pump that brings
innovation and combines form with function, essential qualities in a
device that patients have to interact with 24/7," says Dr. Pratik
Choudhary, Clinical Lecturer in Diabetes at King's College London.
Cellnovo's ground breaking technology means that diabetes
therapies can now be managed more easily, accurately and
intuitively. The patch pump is the smallest and most precise ever
developed, and the touch screen, wireless handset is instantly
familiar to those who have used other mobile devices such as Apple's
"Cellnovo has combined advanced mobile and medical
technology which may create a paradigm shift in diabetes care," says
Irl B. Hirsch, Professor of Medicine, University of Washington,
Seattle, USA. "For the multitude of patients who could benefit from
pump therapy, Cellnovo could be a game-changer."
"The ability to see real-time
data of patients who may be hundreds of miles away provides the
opportunity to redefine our care model," says Dr. Mark Evans,
Lecturer and Honorary Consultant at the Institute of Metabolic
Science at the University of Cambridge.